In the latest NCCN guideline7 and 2017‐European LeukemiaNet recommendation,8NPM1mut AML is divided into favorable‐ and intermediate‐risk groups according to a presence or absence of concomitant FLT3‐ITD and allele ratio (AR) levels. The gene discussed is FLT3; the disease is acute myeloid leukemia.